NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Socinski, M., Creelan, B., Horn, L., Reck, M., Paz-Ares, L., Steins, M., Felip, E., van den Heuvel, M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Geese, W.J., Bhagavatheeswaran, P., Chen, A., Carbone, D.P.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis
Published in The New England journal of medicine (31.05.2018)
Published in The New England journal of medicine (31.05.2018)
Get full text
Journal Article
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Vokes, E.E., Ready, N., Felip, E., Horn, L., Burgio, M.A., Antonia, S.J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L.Q.M., Blumenschein, G., Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W.J., Li, A., Healey, D., Crinò, L.
Published in Annals of oncology (01.04.2018)
Published in Annals of oncology (01.04.2018)
Get full text
Journal Article
4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
Ramalingam, S.S., Balli, D., Ciuleanu, T-E., Pluzanski, A., Lee, J-S., Schenker, M., Bernabe Caro, R., Lee, K.H., Bartolucci, R., Audigier-Valette, C., Hellmann, M.D., Paz-Ares, L.G., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K., Tran, P., Spires, T., Geese, W.J., Agrawal, S.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, Robert L., Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin, Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Iglesias Docampo, Lara C., Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Monga, Manish, Lynch, Mark, Geese, William J., Kopit, Justin, Shaw, James W., Gillison, Maura L.
Published in The New England journal of medicine (10.11.2016)
Published in The New England journal of medicine (10.11.2016)
Get full text
Journal Article
A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Argiris, A., Gillison, M., Ferris, R.L., Harrington, K., Sanchez, T.K., Baudelet, C., Geese, W.J., Shaw, J., Haddad, R.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
Peters, S., Ramalingam, S.S., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Nathan, F.E., Hellmann, M.D.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA4_PR - Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
Peters, S., Ramalingam, S.S., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Nathan, F.E., Hellmann, M.D.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)
Paz-Ares, L., Brahmer, J., Hellmann, M.D., Reck, M., O'Byrne, K., Borghaei, H., Geese, W.J., Lu, H., Nathan, F.E., Ramalingam, S.
Published in Annals of oncology (01.04.2017)
Published in Annals of oncology (01.04.2017)
Get full text
Journal Article
Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714
Haddad, R., Gillison, M., Ferris, R.L., Harrington, K., Monga, M., Baudelet, C., Geese, W.J., Argiris, A.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
Barlesi, F., Steins, M., Horn, L., Ready, N., Felip, E., Borghaei, H., Spigel, D.R., Arrieta, O., Antonia, S.J., Fayette, J., Rizvi, N., Crinò, L., Reck, M., Eberhardt, W.E., Hellmann, M., Geese, W.J., Li, A., Healey, D., Brahmer, J.R., Paz-Ares, L.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Felip Font, E., Gettinger, S.N., Burgio, M.A., Antonia, S.J., Holgado, E., Spigel, D.R., Arrieta, O., Domine Gomez, M., Aren Frontera, O., Brahmer, J., Chow, L.Q., Crinò, L., Butts, C., Coudert, B., Horn, L., Steins, M., Geese, W.J., Li, A., Healey, D., Vokes, E.E.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article